MGMT and central nervous system cancer: Various genetic or molecular features have been identified that play a role in determining the treatment response and prognosis in gliomas, including IDH mutation, 1p/19q codeletion, O-6-methylguanine-DNA methyltransferase (MGMT) methylation, telomerase reverse transcriptase (TERT) promoter mutation, epidermal growth factor receptor (EGFR) amplification, and tumor protein TP53 mutation.